Relay Therapeutics Net Income

The latest net income for RLAY is $-290M as of June 2026. That compares with $-310M in the prior-year period — up 8.2% year over year. That is below the Healthcare sector average of $16B. Investors often review this figure alongside Relay Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, RLAY's net income moved from $-310M to $-290M — a 8.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Relay Therapeutics's operating scale or balance-sheet position.

Against Healthcare companies, RLAY currently prints $-290M for net income, while the sector average sits near $16B. That is roughly 101.8% below the sector mean. Large gaps often invite a closer look at Relay Therapeutics's growth, margins, and balance sheet.

A net income figure of $-290M for RLAY is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $16B. Explore the charts below for those layers of context.

After noting RLAY's net income ($-290M), review year-over-year change from $-310M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.